OOIR: Observatory of International Research

Papers

(The H4-Index of npj Precision Oncology is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Patient-derived organoids as a predictive biomarker for treatment response in cancer patients	140
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population	96
High expression of ACE2 and TMPRSS2 and clinical characteristics of COVID-19 in colorectal cancer patients	71
Blood-derived lncRNAs as biomarkers for cancer diagnosis: the Good, the Bad and the Beauty	66
Microbiome dysbiosis in lung cancer: from composition to therapy	64
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma	64
Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance	61
Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients	61
Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity	60
Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy	56
GD2 CAR T cells against human glioblastoma	50
The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response	50
Genetic mutation and biological pathway prediction based on whole slide images in breast carcinoma using deep learning	47
Will polygenic risk scores for cancer ever be clinically useful?	43
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors	42
Clinical application of a lung cancer organoid (tumoroid) culture system	40
Antibody-drug conjugates in lung cancer: dawn of a new era?	40
Survival improvement for patients with metastatic colorectal cancer over twenty years	40
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes	38
Structural variant detection in cancer genomes: computational challenges and perspectives for precision oncology	38
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer	37
Identification of gastric cancer subtypes based on pathway clustering	36
Deep learning for end-to-end kidney cancer diagnosis on multi-phase abdominal computed tomography	35
Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance	34
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib	34

Dynamic roles of inflammasomes in inflammatory tumor microenvironment	33
High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition	33
Targeting CDK1 in cancer: mechanisms and implications	33
A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors	33
Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)	33
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer	32
A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients	32